These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12787422)

  • 21. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemoglobin variability in epoetin-treated hemodialysis patients.
    Berns JS; Elzein H; Lynn RI; Fishbane S; Meisels IS; Deoreo PB
    Kidney Int; 2003 Oct; 64(4):1514-21. PubMed ID: 12969173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
    Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
    Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
    Killian AD; Gupta V; Goetz AE
    Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F; Smith C; Mody S; McKenzie RS; Bookhart B; Piech CT
    Am J Ther; 2007; 14(4):322-7. PubMed ID: 17667204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
    Zehnder C; Blumberg A
    Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
    Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
    Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor.
    Di Iorio B; De Nicola L; Bellizzi V; Minutolo R; Zamboli P; Rubino R; Fuiano G; Conte G
    Blood Purif; 2004; 22(5):453-60. PubMed ID: 15359104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients.
    MacLaren R; Sullivan PW
    Value Health; 2005; 8(2):105-16. PubMed ID: 15804319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between resistance to erythropoietin and high anomalous hemoglobin levels in hemodialysis patients with beta-thalassemia minor.
    Di Iorio B; Guastaferro P; Bellizzi V
    Blood Purif; 2003; 21(6):376-80. PubMed ID: 14586179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
    Raymond CB; Collins DM; Bernstein KN; Skwarchuk DE; Vercaigne LM
    Nephron Clin Pract; 2006; 102(3-4):c88-92. PubMed ID: 16282700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa.
    Capelli JP; Kushner H
    Nephrol News Issues; 2006 Mar; 20(3):33, 35, 39 passim. PubMed ID: 16532992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudi Arabia.
    Shaheen FA; Akeel N; Alfi A; Harbi A; Tarif N; Souqiyyeh MZ
    Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):365-72. PubMed ID: 16970257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
    Spinowitz B; Coyne DW; Lok CE; Fraticelli M; Azer M; Dalal S; Villa G; Rosansky S; Adamis H; Beyer U;
    Am J Nephrol; 2008; 28(2):280-9. PubMed ID: 18004064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.